Brivaracetam

證據等級: L5

預測適應症: 10 個

Brivaracetam: From Focal-Onset Epilepsy to Status Epilepticus

One-Sentence Summary

Brivaracetam is a high-affinity SV2A ligand originally developed and used as adjunctive therapy for focal-onset (partial) seizures in epilepsy. Among the ten indications predicted by the TxGNN model, Status Epilepticus shows by far the strongest supporting evidence and is the focus of this report, with 2 clinical trials (including one direct head-to-head comparison with levetiracetam) and 19 publications currently supporting this direction.

Quick Overview

Item	Content
Original Indication	Focal-onset (partial) seizures / epilepsy, adjunctive treatment (inferred from literature; no Norway license text available)
Predicted New Indication	Status Epilepticus
TxGNN Prediction Score	99.40%
Evidence Level	L2
Norway Market Status	Not marketed
Number of Authorizations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in the evidence pack (data gap, DG002). Based on known information from the literature, brivaracetam is a high-affinity, selective ligand of synaptic vesicle protein 2A (SV2A), structurally related to levetiracetam but with 15- to 30-fold greater binding affinity and faster brain penetration. Its efficacy in focal-onset epilepsy has been established through multiple Phase 3 trials and is now supported for status epilepticus by real-world and registry data.

Status epilepticus (SE) is, pathophysiologically, a failure of the mechanisms that normally terminate a seizure — it is a continuation and intensification of the same underlying seizure biology already targeted by brivaracetam in its approved indication. Levetiracetam, the parent compound acting on the same SV2A target, is already widely used intravenously in SE management, making brivaracetam's extension into this indication a class-effect extrapolation rather than a novel mechanistic hypothesis.

Mechanistically, brivaracetam's rapid blood-brain-barrier penetration and available intravenous formulation are particularly well suited to the emergency treatment setting of SE, where fast onset of action is critical. This combination of established SV2A pharmacology, an IV formulation, and accumulating multicenter registry and comparative trial data supports the plausibility of this predicted indication.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT07163572	N/A	Completed	152	Direct comparison of IV brivaracetam vs. IV levetiracetam for acute management of pediatric status epilepticus; addresses the current gap in pediatric SE data for brivaracetam.
NCT07443241	N/A	Completed	779	Retrospective real-world study of sex-related differences in etiology, diagnostics, treatment, and outcomes of SE (2011–2023 cohort); includes treatment data but not brivaracetam-specific.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
32278203	2020	Systematic Review	J Neurol Sci	Efficacy/tolerability of IV brivaracetam for SE; notes sparse controlled trial data limiting current recommendation strength.
41838218	2026	Systematic Review	J Neurol	Most recent systematic review of brivaracetam for SE; evaluates efficacy and safety across accumulated studies.
31342405	2019	Systematic Review	CNS Drugs	IV brivaracetam in SE treatment; highlights favorable pharmacokinetics for emergency use.
32822230	2020	Review	Epilepsy Currents	AES Treatments Committee comprehensive review of refractory convulsive SE; evaluates 8 parenteral ASMs including brivaracetam as third-line option.
26891946	2016	Review	Expert Rev Clin Pharmacol	Brivaracetam in focal/idiopathic generalized epilepsies and SE; summarizes seizure reduction and responder rates across dose ranges.
36528008	2023	Review (photosensitivity model)	Epilepsy & Behavior	Compares brivaracetam and levetiracetam using the photosensitivity/EEG biomarker model as a lens for SE treatment decisions.
31260101	2019	Multicenter Registry	Epilepsia	Multicenter evaluation of IV brivaracetam use in SE, supported by preclinical effectiveness in animal SE models.
33561784	2021	Multicentric Retrospective Study	Seizure	Italian multicenter retrospective study evaluating use, effectiveness, and adverse events of IV brivaracetam in SE.
30530123	2019	Cohort/PK Study	Epilepsy Research	Correlates IV brivaracetam loading dose and plasma levels with clinical response in SE patients.
32480279	2020	Case Report	Seizure	Case report describing use of brivaracetam in absence status epilepticus.

Norway Market Information

Currently not marketed in Norway — no local authorization/license data is available for this product.

Safety Considerations

Please refer to the package insert for safety information.

(Note: key warnings, contraindications, and drug-drug interaction data are all currently unavailable — DG001 identifies this as a blocking gap for the S1 safety review stage.)

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: One completed head-to-head trial (IV brivaracetam vs. levetiracetam, N=152) plus multiple systematic reviews and multicenter registry studies support the use of IV brivaracetam in status epilepticus, consistent with the already-established use of the same-class SV2A ligand levetiracetam in this setting. This corresponds to Evidence Level L2 — sufficient to proceed cautiously, but not yet to a full "Go" given the absence of a dedicated adult RCT.

To proceed, the following is needed:

Local regulatory/label data (TFDA/EMA package insert warnings and contraindications) — currently a blocking data gap (DG001)
Drug-drug interaction data (current DDI query returned "not found")
Formal mechanism-of-action documentation for regulatory submission (DG002)
A prospective RCT in the adult SE population, as the strongest current comparative trial is in pediatric patients
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.